Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation develops and sells cannabis products for adult-use and medical markets, with common shares trading as CGC on Nasdaq and WEED on the TSX. Company updates frequently cover Canadian brand activity across Tweed, Deelish, 7ACRES, DOJA, Deep Space and related formats including flower, pre-rolls, vapes, softgels and minor cannabinoid products.
News also centers on medical cannabis services through Canada House Clinics and the Abba Medix online channel, Storz & Bickel vaporization devices, operating and financial results, capital-structure actions, shareholder voting matters and governance changes. Canopy Growth also discloses its unconsolidated, non-controlling interest in Canopy USA as exposure to the U.S. THC market.
Canopy Growth (Nasdaq: CGC) is relaunching its Tweed brand in Germany’s medical cannabis market, introducing three MTL-developed strains: Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes. Up to five more strains are planned for June 2026.
The move is the first international product release following the MTL acquisition. Canopy Growth also received a management cease trade order from the Ontario Securities Commission on May 28, 2026, and plans to refile affected financial statements in a comprehensive Form 10-K by June 15, 2026.
Canopy Growth (Nasdaq: CGC) will release its fourth quarter and fiscal year 2026 results, along with restated 2024 and 2025 figures, before markets open on June 15, 2026.
The company identified a non-cash warrant classification error and plans a refiling that, according to management, is not expected to impact revenue, cash flow, key metrics, liquidity, or debt covenants. Canopy has applied for a management cease trade order until the refiling is complete and will host an investor webcast on June 15, 2026 at 10:00 AM ET.
Canopy Growth (NASDAQ: CGC) and Spectrum Therapeutics expanded their Minor Cannabinoid softgel lineup with new 30- and 90-pack formats and added dosing options across the Optimized Spectrum portfolio. Clarity, Unwind, and Daily Relief 90-packs are available now; two SKUs (30-pack Daily Relief higher-dose, 90-pack Nighttime Relief) roll out at the end of May.
The portfolio adds daytime and nighttime formulations, a higher-dose 30-pack, and aims to improve dosing flexibility, patient adherence, affordability, and clinical alignment.
Canopy Growth (NASDAQ: CGC) unveiled a national summer refresh for its Tweed brand titled “There’s a Tweed for That.” The campaign launches over the Victoria Day long weekend and highlights updated packaging, three new flower strains, Quickies pre-rolls, improved potency, sharper pricing, and a new milled format coming summer 2026.
The refresh adds window bags so consumers can see flower SKUs, and the lineup includes whole and milled flower, pre-rolls, Liquid Diamond vapes and softgels.
Canopy Growth (CGC) launched a new value-focused cannabis brand, Deelish, on March 31, 2026, offering high-potency flower and pre-rolls at everyday price points.
Deelish debuts four SKUs: two 28g whole-flower SKUs and two 2x1g pre-roll SKUs, with flower testing 27%-33% THC and pre-rolls 26%-32% THC. The brand features rotating genetics and is now available at select stores in Ontario and Alberta.
Canopy Growth (NASDAQ: CGC, TSX: WEED) said its Apollo Cannabis Clinics was named Best Medical Cannabis Clinic in the 2025 Toronto Star Readers’ Choice Awards on March 30, 2026. The award reflects public voting and patient trust in Apollo’s care.
Apollo offers Canada-wide, free fully virtual medical cannabis consultations with no referral required, personalized treatment plans, and ongoing support. According to the company, Apollo has helped thousands of Canadians manage chronic pain, anxiety, sleep disorders, PTSD, and other conditions.
Canopy Growth (Nasdaq: CGC) announced that David Männer will become Managing Director of Storz & Bickel effective April 1, 2026, succeeding co-founder Jürgen Bickel, who is transitioning after 25 years of leadership. Männer is a 14-year company veteran and most recently served as Deputy Managing Director.
Canopy said the move preserves operational continuity, supports plans to deepen presence in the U.S., and intends to continue product innovation under new leadership.
Canopy Growth (Nasdaq: CGC; TSX: WEED) completed its acquisition of MTL Cannabis on March 16, 2026, creating Canada’s leading medical cannabis business by revenue. The deal: MTL became a wholly owned subsidiary, MTL shares to be de-listed, and consideration included 0.32 Canopy shares plus $0.144 cash per MTL share.
The transaction issued ~41.2 million Canopy shares and paid ~$18.5 million cash. Expected run-rate synergies are ~$10 million within 18 months and the combined business supports a path to positive adjusted EBITDA in fiscal 2027.
Canopy Growth (Nasdaq: CGC) said MTL Cannabis shareholders overwhelmingly approved Canopy’s acquisition plan at a Feb 17, 2026 special meeting.
The vote saw 99.97% approval of all MTL shares and ~89% turnout. Closing remains subject to customary conditions and is expected before the end of March 2026.
Canopy Growth (Nasdaq: CGC) reported Q3 FY2026 results for the three months ended December 31, 2025, showing improving fundamentals in Canada and narrowing losses.
Key highlights: consolidated net revenue of $75M, cannabis net revenue of $52M, adjusted EBITDA loss narrowed to $3M, net loss narrowed 49% YoY, cash and equivalents $371M, net cash position $146M. Acquisition of MTL Cannabis on track to close in the current quarter.